SCB-2019
SCB-2019 Uses, Dosage, Side Effects, Food Interaction and all others data.
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.
The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.
Trade Name | SCB-2019 |
Generic | SCB-2019 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here SCB-2019